[96a5a0]: / output / allTrials / identified / NCT04541420_identified.json

Download this file

151 lines (151 with data), 5.9 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
{
"info": {
"nct_id": "NCT04541420",
"official_title": "An Observational, Retrospective Study of Eribulin in Advanced Breast Cancer",
"inclusion_criteria": "1. Advanced breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.\n2. Eribulin treatment of advanced breast cancer for at least one cycle, between Dec 2019 and Aug 2020.\n3. Available medical history.\nHealthy volunteers allowed\nMust be FEMALE",
"exclusion_criteria": "1. Incomplete medical history.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "1. Advanced breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.",
"criterions": [
{
"exact_snippets": "Advanced breast cancer included unresectable locally advanced breast cancer",
"criterion": "unresectable locally advanced breast cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Advanced breast cancer included ... de novo stage IV breast cancer",
"criterion": "de novo stage IV breast cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Advanced breast cancer included ... recurrent metastatic breast cancer",
"criterion": "recurrent metastatic breast cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "2. Eribulin treatment of advanced breast cancer for at least one cycle, between Dec 2019 and Aug 2020.",
"criterions": [
{
"exact_snippets": "Eribulin treatment of advanced breast cancer",
"criterion": "Eribulin treatment",
"requirements": [
{
"requirement_type": "condition",
"expected_value": "advanced breast cancer"
}
]
},
{
"exact_snippets": "at least one cycle",
"criterion": "Eribulin treatment",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "cycle"
}
}
]
},
{
"exact_snippets": "between Dec 2019 and Aug 2020",
"criterion": "Eribulin treatment",
"requirements": [
{
"requirement_type": "time period",
"expected_value": "between Dec 2019 and Aug 2020"
}
]
}
]
},
{
"line": "3. Available medical history.",
"criterions": [
{
"exact_snippets": "Available medical history.",
"criterion": "medical history",
"requirements": [
{
"requirement_type": "availability",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be FEMALE",
"criterions": [
{
"exact_snippets": "Must be FEMALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "value",
"expected_value": "female"
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "1. Incomplete medical history.",
"criterions": [
{
"exact_snippets": "Incomplete medical history",
"criterion": "medical history",
"requirements": [
{
"requirement_type": "completeness",
"expected_value": false
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}